Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. APGE
6. GOOGL
7. MSTR
8. HOOD
9. ABBV
10. LLY

Go back to Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
(NASDAQ: ABUS) Delayed: 4.74 +0.19 (4.18%)
Previous Close $4.55    52 Week High $5.88 
Open $4.60    52 Week Low $2.65 
Day High $4.79    P/E N/A 
Day Low $4.59    EPS $0.00 
Volume 504,724       

(NASDAQ: ABUS) Delayed: 4.74 +0.19 (4.18%)
Previous Close $4.55    52 Week High $5.88 
Open $4.60    52 Week Low $2.65 
Day High $4.79    P/E N/A 
Day Low $4.59    EPS $0.00 
Volume 504,724